Home Companies Catalysts Deep Dives
STACCATO alprazolam alprazolam PHASE3
Drug Profile
ModalitySmall molecule (inhaled)
RouteInhaled
Therapy AreaNeurology
Peak Sales Est$500M
Formulations[]
Companies
UCB (ORIGINATOR)100%
Mechanism: GABA-A receptor modulator (benzodiazepine)
Expert: Enhances GABA-A receptor activity for rapid seizure control
Everyday: Enhances GABA-A receptor activity for rapid seizure control
Targets: ["GABA-A"]
Programs (1)
IndicationStageKey StudyRegional Status
Stereotypical prolonged seizuresPHASE3Phase 3[]
Upcoming Catalysts (1)
STACCATO Alprazolam - Seizures - Ph3 - Headline Results H1 2026
Notes
Inhaled alprazolam using STACCATO vaporization technology for rapid treatment of seizure clusters. Novel delivery enables faster onset than oral benzodiazepines, targeting rescue therapy in epilepsy patients.
Data from Supabase · Updated 2026-03-24